Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. (Q46146753)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22676385%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22676385%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22676385%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Warren G Linley

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22676385%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

1 reference

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22676385%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22676385%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22676385%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22676385%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

779-794

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22676385%20AND%20SRC:MED&resulttype=core&format=json

Ontario's formulary committee: how recommendations are made.

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

Pharmacoeconomic evaluation in Ireland: a review of the process

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

Medicines regulation and health technology assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

De testimonio: on the evidence for decisions about the use of therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

Drugs for exceptionally rare diseases: do they deserve special status for funding?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

NICE and new: appraising innovation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591530-000000000-00000

A Stated Preference Binary Choice Experiment to Explore NICE Decision Making

21 January 2018

1 reference

12 December 2020

“Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making

1 reference

12 December 2020

Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996)

1 reference

12 December 2020

Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?

1 reference

12 December 2020

Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature.

1 reference

12 December 2020

Inter-provincial variation in government drug formularies

1 reference

12 December 2020